Orgenesis Stock Probability Of Bankruptcy
| ORGS Stock | USD 0.51 0.01 2.00% |
Orgenesis | Probability Of Bankruptcy |
Orgenesis Company probability of financial unrest Analysis
Orgenesis' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Orgenesis Probability Of Bankruptcy | Over 69% |
Most of Orgenesis' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orgenesis is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Orgenesis probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Orgenesis odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Orgenesis financial health.
Is Orgenesis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orgenesis. If investors know Orgenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orgenesis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.018 | Quarterly Revenue Growth (0.99) | Return On Assets (0.62) | Return On Equity (3.39) |
The market value of Orgenesis is measured differently than its book value, which is the value of Orgenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Orgenesis' value that differs from its market value or its book value, called intrinsic value, which is Orgenesis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orgenesis' market value can be influenced by many factors that don't directly affect Orgenesis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orgenesis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Orgenesis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orgenesis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Orgenesis Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for Orgenesis is extremely important. It helps to project a fair market value of Orgenesis Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Orgenesis' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Orgenesis' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Orgenesis' interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Orgenesis has a Probability Of Bankruptcy of 69%. This is 59.39% higher than that of the Biotechnology sector and 25.82% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 73.24% lower than that of the firm.
Orgenesis Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orgenesis' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Orgenesis could also be used in its relative valuation, which is a method of valuing Orgenesis by comparing valuation metrics of similar companies.Orgenesis is currently under evaluation in probability of bankruptcy category among related companies.
Orgenesis Main Bankruptcy Drivers
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Debt | (32.0M) | 6.4M | 15.0M | 21.8M | 25.1M | 26.3M | |
| Total Current Liabilities | 17.2M | 16.3M | 15.4M | 15.9M | 16.4M | 11.9M | |
| Non Current Liabilities Total | 8.7M | 5.8M | 15.7M | 19.1M | 22.0M | 16.6M | |
| Total Assets | 73.9M | 77.7M | 59.8M | 90.9M | 14.6M | 38.8M | |
| Total Current Assets | 28.1M | 50.1M | 25.8M | 46.3M | 4.1M | 15.1M | |
| Total Cash From Operating Activities | (12.9M) | (78.0M) | (26.9M) | (24.9M) | (14.8M) | (13.6M) |
Orgenesis Fundamentals
| Return On Equity | -3.39 | ||||
| Return On Asset | -0.62 | ||||
| Operating Margin | (32.13) % | ||||
| Current Valuation | 38.84 M | ||||
| Shares Outstanding | 34.34 M | ||||
| Shares Owned By Insiders | 20.35 % | ||||
| Shares Owned By Institutions | 6.56 % | ||||
| Number Of Shares Shorted | 299.69 K | ||||
| Price To Earning | 7.52 X | ||||
| Price To Book | 1.39 X | ||||
| Price To Sales | 0.61 X | ||||
| Revenue | 530 K | ||||
| Gross Profit | 36.02 M | ||||
| EBITDA | (54.07 M) | ||||
| Net Income | (64.92 M) | ||||
| Cash And Equivalents | 2.3 M | ||||
| Cash Per Share | 0.09 X | ||||
| Total Debt | 22.62 M | ||||
| Debt To Equity | 0.64 % | ||||
| Current Ratio | 1.57 X | ||||
| Book Value Per Share | (0.66) X | ||||
| Cash Flow From Operations | (14.84 M) | ||||
| Short Ratio | 3.78 X | ||||
| Earnings Per Share | (1.91) X | ||||
| Target Price | 6.0 | ||||
| Beta | 1.1 | ||||
| Market Capitalization | 17.2 M | ||||
| Total Asset | 14.55 M | ||||
| Retained Earnings | (176.62 M) | ||||
| Working Capital | (12.33 M) | ||||
| Current Asset | 5.29 M | ||||
| Current Liabilities | 14.92 M | ||||
| Net Asset | 14.55 M |
About Orgenesis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Orgenesis's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orgenesis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orgenesis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Orgenesis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Orgenesis' short interest history, or implied volatility extrapolated from Orgenesis options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Orgenesis Piotroski F Score and Orgenesis Altman Z Score analysis. For more information on how to buy Orgenesis Stock please use our How to Invest in Orgenesis guide.Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Orgenesis Stock analysis
When running Orgenesis' price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is Orgenesis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orgenesis. If investors know Orgenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orgenesis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.018 | Quarterly Revenue Growth (0.99) | Return On Assets (0.62) | Return On Equity (3.39) |
The market value of Orgenesis is measured differently than its book value, which is the value of Orgenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Orgenesis' value that differs from its market value or its book value, called intrinsic value, which is Orgenesis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orgenesis' market value can be influenced by many factors that don't directly affect Orgenesis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orgenesis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Orgenesis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orgenesis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.